DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2009/0232941 A1 Farmer (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2009/0232941 A1 Farmer (43) Pub US 20090232941A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0232941 A1 Farmer (43) Pub. Date: Sep. 17, 2009 (54) BEVERAGE COMPOSITIONS Related U.S. Application Data (76) Inventor: Sean Farmer, Miami Beach, FL (60)60) ProvisionalTyga applicauonapplication No.No 60/999.243Z43, Tilledfiled onOn Oct.UC (US) s Publication Classification Correspondence Address: (51) Int. Cl. MINTZ, LEVIN, COHN, FERRIS, GLOVSKY A23G L/42 (2006.01) AND POPEO, PC A23F 5/00 (2006.01) ONE FINANCIAL CENTER A23F 3/4 (2006.01) BOSTON, MA 02111 (US) (52) U.S. Cl. .......................................................... 426/61 (21) Appl. No.: 12/253,048 (57) ABSTRACT The present invention describes beverage compositions com (22) Filed: Oct. 16, 2008 prising lactic acid-producing bacteria. Patent Application Publication Sep. 17, 2009 US 2009/0232941 A1 ( bwe ceasec urth 'rity Aacillus coagulons / &acts coat veins N- -la. (everage coefosi En US 2009/0232941 A1 Sep. 17, 2009 BEVERAGE COMPOSITIONS 0008 Bacillus coagulans bacteria are included in the bev erage compositions of this invention. Bacterial species RELATED APPLICATIONS include Bacillus coagulans, e.g., Bacillus coagulans ham mer, preferably Bacillus coagulans hammer Strain Accession 0001. This application claims the benefit of U.S. Ser. No. No. ATCC 31284, or one or more strains derived from Bacil 60/999.243, filed Oct. 16, 2007, which is incorporated herein lus coagulans hammer strain Accession No. ATCC 31284 by reference in its entirety. (e.g., ATCC Numbers: GBI-20, ATCC Designation Number PTA-6085; GBI-30, ATCC Designation Number PTA-6086: FIELD OF THE INVENTION and GBI-40, ATCC Designation Number PTA-6087; see U.S. 0002 The present application relates to beverage compo Pat. No. 6,849.256 to Farmer). sitions comprising lactic acid-producing bacteria. 0009 Preferably, the isolated Bacillus coagulans is in the form of a spore. The invention provides for the activation of BACKGROUND OF THE INVENTION Bacillus coagulans spores upon contacting hot liquid. In one aspect, the hot liquid is water. 0003. The gastrointestinal microflora plays a number of 0010 Optionally, the isolated Bacillus coagulans is in the Vital roles in maintaining gastrointestinal tract function and form of a vegetative cell. In another aspect, the isolated Bacil overall physiological health. The growth and metabolism of lus coagulans is in the form of a mixture of vegetative cells the many individual bacterial species inhabiting the gas and spores. trointestinal tract depend primarily upon the Substrates avail 0011. The invention also provides for beverage composi able to them, most of which are derived from the diet. (See tions including an isolated Bacillus coagulans bacterium and e.g., Gibson G. R. et al., 1995. Gastroenterology 106: 975 one or more non-bacterial ingredients, such as coffee beans or 982: Christl, S.U. et al., 1992. Gut 33: 1234-1238.) Probiotic fragments thereof, coffee powder, chocolate powder, and organisms are non-pathogenic, non-toxigenic, retain viability cocoa powder. Exemplary beverage compositions include during storage, and Survive passage through the stomach and coffee, hot chocolate, and hot cocoa. Optionally, the beverage Small intestine. Since probiotics do not generally perma composition is instant coffee or brewable coffee. In one nently colonize the host, they need to be ingested regularly for aspect, the beverage composition is decaffeinated coffee. any health promoting properties to persist. These findings Optionally, Bacillus coagulans bacteria in the form of spray have led to attempts to modify the composition and metabolic dried powder is added directly to the dry beverage composi activities of the bacterial community through diet, primarily tion itself or to the brewed or reconstituted beverage liquid. with probiotics, which are live microbial food supplements. 0012. The Bacillus coagulans Hammer strains of the invention are non-pathogenic and generally regarded as safe SUMMARY OF THE INVENTION for use in human nutrition (i.e., GRAS classification) by the 0004. The invention is directed to the surprising discovery U.S. Federal Drug Administration (FDA) and the U.S. that lactic acid-producing bacteria, particularly Bacillus spe Department of Agriculture (USDA), and by those skilled in cies, remain viable and retain their beneficial probiotic prop the art. Furthermore, the Bacillus coagulans Hammer strains erties in beverage compositions, such as those prepared at of the invention germinate at or below human body tempera high temperatures (e.g., 80, 90, 100, 120, or 150° C.) in ture, rendering them useful as probiotics. Many Bacillus boiling water. The invention describes spore-containing bev coagulans Strains outside the Hammer group have mostly erage compositions. Specifically, the invention provides a industrial applications, little or no nutritional benefit, and beverage composition including an isolated Bacillus coagul environmental contaminants that have not been evaluated for lans bacterium and one or more non-bacterial ingredients. In safety. Moreover, many other non-Hammer strains of Bacil one aspect, the one or more non-bacterial ingredients include lus coagulans grow optimally at temperatures that exceed a dehydrated vegetative matter. human body temperature and, thus, do not germinate effi 0005 Optionally, the dehydrated vegetative matter is ciently in the human body. Such strains are less or not suitable obtained from Camelia sinensis. In one aspect, the dehy as probiotics for human consumption. drated vegetative matter is processed leaves, buds, roots and/ 0013 Cited publications are incorporated herein by refer or twigs. Preferably, the beverage composition is green tea, ence. Both the foregoing general description and the follow black tea, oolong tea, yellow tea, or white tea. The invention ing detailed description and examples are exemplary and provides instant tea and brewable tea beverage compositions. explanatory only and are not restrictive of the invention as In one aspect, the beverage composition is decaffeinated tea. claimed. 0006 Alternatively, the dehydrated vegetative matter is BRIEF DESCRIPTION OF THE DRAWINGS obtained from a species other than Camelia sinensis. In one aspect, the beverage composition is herbal tea. Suitable 0014 FIG. 1A is a drawing demonstrating that tea leaves herbal teas include rosehip tea, chamomile tea, jiaogulan tea, or other dehydrated vegetative matter is coated or sprayed ginger tea, peppermint tea, fruit tea, jasmine tea, hibiscus tea, with spores or freeze-dried Bacillus coagulans Vegetative lemongrass tea, ginseng tea, and rooibos tea. cells. 0007. In one aspect, the isolated Bacillus coagulans com 0015 FIG. 1B is a drawing illustrating that the Bacillus prise between about 0.1% to about 50% by weight of the bacterium is added to the beverage composition separate from beverage composition. Preferably, the isolated Bacillus or along with the dehydrated vegetative matter or non-bacte coagulans comprise between about 1% and about 10% by rial ingredient. weight of the beverage composition. Most preferably, the amount of Bacillus coagulans bacteria is about 10 colony DETAILED DESCRIPTION OF THE INVENTION forming units (CFU) of bacteria per tea bag (about 50 mg of 0016. The present invention is directed to the discovery bacteria per tea bag in about 2-3 grams of tea). that non-pathogenic lactic acid-producing bacteria (i.e., "lac US 2009/0232941 A1 Sep. 17, 2009 tic acid bacteria'). Such as the exemplary Bacillus coagulans, particularly human bile. By contrast, Bacillus coagulans is remain viable and retain their beneficial probiotic properties able to Survive and colonize the gastrointestinal tract in the in beverage compositions, such as those prepared in boiling bile environment and even grown in this low pH range. Water. Probiotic Activity of Bacillus coagulans Probiotic Lactic Acid-Producing Bacteria 0023. It is well-documented clinically that many species of bacterial, mycotic and yeast pathogens possess the ability 0017. A probiotic lactic acid-producing bacteria suitable to cause a variety of gastrointestinal disorders including, but for use in the methods and compositions of the invention as not limited to: disruption of normal gastrointestinal bio defined for use in the present invention produces acid and is non-pathogenic. There are many suitable bacteria identified chemical function, necrosis of gastrointestinal tissues, and as described herein, although the invention is not limited to disruption of the bioabsorption of nutrients, and like condi currently known bacterial species insofar as the purposes and tions. The probiotic microorganism-containing compositions objectives of the bacteria is described. The property of acid described herein inhibit these pathogens. Thus, the composi production is important to the effectiveness of the probiotic tions are useful in the prophylactic ortherapeutic treatment of lactic acid-producing bacteria of this invention. conditions associated with infection by these aforementioned 0018. The invention provides using a lactic acid-produc pathogens. ing bacteria, such as a spore-forming Bacillus species, such as 0024. In one aspect, a Bacillus coagulans Strain is B. coagulans. Preferably, the spore-forming Bacillus species included in the composition in the form of vegetative cells. of the invention is B. coagulans Hammer. Preferably, the Bacillus coagulans strain is included in the 0019 Exemplary methods and compositions are composition in the form of
Load more

Recommended publications
  • Consolidated Version of the Sanpin 2.3.2.1078-01 on Food, Raw Material, and Foodstuff
    Registered with the Ministry of Justice of the RF, March 22, 2002 No. 3326 MINISTRY OF HEALTH OF THE RUSSIAN FEDERATION CHIEF STATE SANITARY INSPECTOR OF THE RUSSIAN FEDERATION RESOLUTION No. 36 November 14, 2001 ON ENACTMENT OF SANITARY RULES (as amended by Amendments No.1, approved by Resolution No. 27 of Chief State Sanitary Inspector of the RF dated 20.08.2002, Amendments and Additions No. 2, approved by Resolution No. 41 of Chief State Sanitary Inspector of the RF dated15.04.2003, No. 5, approved by Resolution No. 42 of Chief State Sanitary Inspector of the RF dated 25.06.2007, No. 6, approved by Resolution No. 13 of Chief State Sanitary Inspector of the RF dated 18.02.2008, No. 7, approved by Resolution No. 17 of Chief State Sanitary Inspector of the RF dated 05.03.2008, No. 8, approved by Resolution No. 26 of Chief State Sanitary Inspector of the RF dated 21.04.2008, No. 9, approved by Resolution No. 30 of Chief State Sanitary Inspector of the RF dated 23.05.2008, No. 10, approved by Resolution No. 43 of Chief State Sanitary Inspector of the RF dated 16.07.2008, Amendments No.11, approved by Resolution No. 56 of Chief State Sanitary Inspector of the RF dated 01.10.2008, No. 12, approved by Resolution No. 58 of Chief State Sanitary Inspector of the RF dated 10.10.2008, Amendment No. 13, approved by Resolution No. 69 of Chief State Sanitary Inspector of the RF dated 11.12.2008, Amendments No.14, approved by Resolution No.
    [Show full text]
  • WO 2013/116261 A2 8 August 2013 (08.08.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/116261 A2 8 August 2013 (08.08.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every CUD 3/386 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2013/023728 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 30 January 2013 (30.01 .2013) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 12000745.5 3 February 2012 (03.02.2012) EP 12001034.3 16 February 2012 (16.02.2012) EP (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: THE PROCTER & GAMBLE COMPANY GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, [US/US]; One Procter & Gamble Plaza, Cincinnati, Ohio UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 45202 (US).
    [Show full text]
  • Super Greens
    SUPER GREENS SUPPLEMENT FACTS Serving Size: 1 Scoop (10 g) Servings Per Container: 30 Amount Per Serving % Daily Value Calories 25 Total Carbohydrate 6 g 2%* Dietary Fiber 3 g 12%* Sugars 1 g † Protein <1 g <2%* Organic Super Greens, Sprouts & Prebiotic Fiber Blend: 3.5 g Wheat grass, barley grass, spirulina (blue green algae), green pea fiber, oat fiber, flaxseed, blue agave inulin, plum, orange peel, apple fiber, lemon peel, kale, broccoli, spinach, parsley, green cabbage, alfalfa grass, chlorella, green tea, tomato, sweet potato, pumpkin, dandelion root, collard greens, dulse, adzuki sprout, amaranth sprout, buckwheat sprout, chia sprout, flax sprout, garbanzo bean sprout, lentil bean sprout, millet sprout, pumpkin sprout, quinoa sprout, sesame sprout, sunflower sprout Organic Super Foods & Fruits Blend: 3.5 g Beet root, carrot, Organic Berry Blend [acai berry (Euterpe oleracea), apple, banana, bilberry, black currant, blueberry, cherry, elderberry, goji berry (Lycium barbarum), grape, maqui berry (Aristotelia chilensis), papaya, pineapple, pomegranate, raspberry, strawberry], apple, shitake mushroom, reishi mushroom, maitake mushroom, blueberry, raspberry, strawberry, peach, blackberry, lemon, pear, cranberry, grape, pomegranate, cherry, orange Probiotic Blend: 500 million CFU Bacillus coagulans, Lactobacillus rhamnosus, Bifidobacterium bifidum, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus casei, Streptococcus thermophilus * Percent Daily Values are based on a 2,000 calorie diet. † Daily value not established. Other ingredients: Organic tapioca starch, organic guar gum, citric acid, organic natural berry flavor and organic rebaudioside A. .
    [Show full text]
  • AFS – Advances in Food Sciences Continuation of CMTL Founded by F
    AFS – Advances in Food Sciences Continuation of CMTL founded by F. Drawert Production by PSP – Parlar Scientific Publications, Angerstr. 12, 85354 Freising, Germany in cooperation with Lehrstuhl für Chemisch-Technische Analyse und Lebensmitteltechnologie, Technische Universität München, 85350 Freising - Weihenstephan, Germany Copyright © by PSP – Parlar Scientific Publications, Angerstr. 12, 85354 Freising, Germany. All rights are reserved, especially the right to translate into foreign language. No part of the journal may be reproduced in any form- through photocopying, microfilming or other processes- or converted to a machine language, especially for data processing equipment- without the written permission of the publisher. The rights of reproduction by lecture, radio and television transmission, magnetic sound recording or similar means are also reserved. Printed in GERMANY – ISSN 14311431----77377737 © by PSP Volume 24 – No 4. 2002 Advances in Food Sciences 1 © by PSP Volume 24 – No 4. 2002 Advances in Food Sciences AFSAFS---- Editorial Board Chief Editors: Prof. Dr. H. Parlar Institut für Lebensmitteltechnologie und Analytische Chemie, TU München - 85350 Freising-Weihenstephan, Germany - E-mail: [email protected] Dr. G. Leupold Institut für Lebensmitteltechnologie und Analytische Chemie, TU München - 85350 Freising-Weihenstephan, Germany - E-mail: [email protected] CoCo----Editor:Editor: Prof. Dr. R. G. Berger Zentrum Angewandte Chemie, Institut für Lebensmittelchemie, Universität Hannover Wunstorfer Straße 14, 30453 Hannover - E-mail: [email protected] AFSAFS- Advisory Board E. Anklam, I M. Bahadir, D F. Coulston, USA J.M. de Man, CAN N. Fischer, D S. Gäb, D A. Görg, D U. Gill, CAN D. Hainzl, P W.P. Hammes, D D. Kotzias, I F.
    [Show full text]
  • Public Health Impact a Suitable Test for L-Citrulline—
    1 Winter 2016 Public Health Impact A Suitable Test for L-citrulline— How Validated Test Methods May New Dietary Supplements Impact Public Health Reference Standards In the U.S., most newborn babies are screened for rare inborn errors of Below is a list of newly released metabolism (IEM)—a group of genetic disorders caused by a defect in a reference standards: metabolic pathway. Left untreated, these disorders can lead to a host of Botanicals medical and developmental consequences ranging from intellectual 1 disability to severe cognitive impairment and even death. • 2,3,5,4’-Tetrahydroxystilbebe-2- Some of these metabolic errors require the use of amino acids to avoid O-Beta-D-Glucoside the buildup of ammonia in the body. L-citrulline is one such amino acid, • Emodin and it is used for IEM as a medical food, which is regulated by the U.S. Food and Drug Administration (FDA) under the Orphan Drug Act. Medical • Polygonum multiflorum Root Dry foods are distinct within the broader category of foods and need to be Extract administered under the supervision of a healthcare professional • Lonicera japonica Flower Dry specifically to help manage a disease or condition associated with Extract distinctive nutritional requirements. In addition to being marketed as a medical food for IEM, L-citrulline is marketed as a dietary supplement for • Secoxyloganin other purposes. • Lonicera macranthoides Flower Sometimes, the quality control testing done to authenticate ingredients is Dry Extract insufficient to guarantee their quality. That was the case with L-citrulline in Luteolin-7-O-glucoside 2014. • One of the primary suppliers of the ingredient for use as a medical food voluntarily recalled several batches of the product after the FDA warned Non-Botanicals that the product being sold had no L-citrulline present.
    [Show full text]
  • Dietary Supplements Compendium Volume 1
    2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs .
    [Show full text]
  • Potential Use of Bacillus Coagulans in the Food Industry
    foods Review Potential Use of Bacillus coagulans in the Food Industry Gözde Konuray * ID and Zerrin Erginkaya ID Department of Food Engineering, Cukurova University, Adana 01330, Turkey; [email protected] * Correspondence: [email protected]; Tel.: +90-322-338-60-84 Received: 1 May 2018; Accepted: 11 June 2018; Published: 13 June 2018 Abstract: Probiotic microorganisms are generally considered to beneficially affect host health when used in adequate amounts. Although generally used in dairy products, they are also widely used in various commercial food products such as fermented meats, cereals, baby foods, fruit juices, and ice creams. Among lactic acid bacteria, Lactobacillus and Bifidobacterium are the most commonly used bacteria in probiotic foods, but they are not resistant to heat treatment. Probiotic food diversity is expected to be greater with the use of probiotics, which are resistant to heat treatment and gastrointestinal system conditions. Bacillus coagulans (B. coagulans) has recently attracted the attention of researchers and food manufacturers, as it exhibits characteristics of both the Bacillus and Lactobacillus genera. B. coagulans is a spore-forming bacterium which is resistant to high temperatures with its probiotic activity. In addition, a large number of studies have been carried out on the low-cost microbial production of industrially valuable products such as lactic acid and various enzymes of B. coagulans which have been used in food production. In this review, the importance of B. coagulans in food industry is discussed. Moreover, some studies on B. coagulans products and the use of B. coagulans as a probiotic in food products are summarized. Keywords: Bacillus coagulans; probiotic; microbial enzyme 1.
    [Show full text]
  • Isolation and Characterization of Probiotic Bacillus Subtilis MKHJ 1-1 Possessing L-Asparaginase Activity
    applied sciences Article Isolation and Characterization of Probiotic Bacillus subtilis MKHJ 1-1 Possessing L-Asparaginase Activity Hyeji Lim 1 , Sujin Oh 1 , Sungryul Yu 2 and Misook Kim 1,* 1 Department of Food Science and Nutrition, Dankook University, Cheonan 31116, Korea; [email protected] (H.L.); [email protected] (S.O.) 2 Department of Clinical Laboratory Science, Semyung University, Jecheon 27136, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-41-550-3494 Abstract: The purpose of this study was to isolate functional Bacillus strains from Korean fermented soybeans and to evaluate their potential as probiotics. The L-asparaginase activity of MKHJ 1-1 was the highest among 162 Bacillus strains. This strain showed nonhemolysis and did not produce β-glucuronidase. Among the nine target bacteria, MKHJ 1-1 inhibited the growth of Escherichia coli, Pseudomonas aeruginosa, Shigella sonnei, Shigella flexneri, Klebsiella pneumoniae, Staphylococcus aureus, and Bacillus cereus. 16S rRNA gene sequence analysis resulted in MKHJ 1-1 identified as Bacillus subtilis subsp. stercoris D7XPN1. As a result of measuring the survival rate in 0.1% pepsin solution (pH 2.5) and 0.3% bile salt solution for 3 h, MKHJ 1-1 exhibited high acid resistance and was able to grow in the presence of bile salt. MKHJ 1-1 showed outstanding autoaggregation ability after 24 h. In addition, its coaggregation with pathogens was strong. Therefore, MKHJ 1-1 is a potential probiotic with L-asparaginase activity and without L-glutaminase activity, suggesting that it could be a new resource for use in the food and pharmaceutical industry.
    [Show full text]
  • BIOMEFX RECOMMENDATIONS 2 Dysbiosis Ratios
    REPORT RECOMMENDATIONS 02....................................... ALPHA AND BETADIVERSITY RESISTOME DYSBIOSIS RATIOS Firmicutes: Bacteroidetes, Proteobacteria:Actinobacteria, Prevotella:Bacteroides Ratio 04....................................... PATHOGENS Clostridium dicile, Helicobacter pylori, Campylobacter species: C. concisus, C. showae, C. hominis, C. ureolyticu, Escherichia coli, Salmonella enterica, Yersinia enterocolitica, Klebsiella pneumoniae (opportunistic), Citrobacter freundii, Hafnia alvei (opportunistic), Raoultella ornithinolytica, Bilophila wadsworthia, Vibrio cholerae, Candida species, Geotrichum spp, Microsporidia spp, Rhodotorula spp, Giardia lamblia, Cyclospora cayetanensis, Blastocystis hominis, Cryptosporidium, Entamoeba histolytica, Adenovirus, Cytomegalovirus, Epstein Barr virus 12 ....................................... FUNCTIONS Saccharolytic Fermentation, Butyrate production, Propionate production, Acetate Production, Lactate production, Proteolytic fermentation, Polyamine production, P-cresol production, Ammonia production, Hydrogen Sulfide production, Methane Production, GABA Production, Glutathione production, Indole production, Estrobolome (estrogen recycling), Vitamin Production, Vit B1 Thiamin, Vit B2 Riboflavin, Vit B5 - Pantothenic acid, Vit B6 - Pyridoxine, Vit B7 - Biotin, Vit B9 - Folate, Vit B12 - Cobalamin, Vitamin K2 23....................................... KEYSTONE SPECIES Akkermansia muciniphila, Faecalibacterium prausnitzii, Butyricicoccus pullicaecorum, Ruminococcus bromii, Ruminococcus flavefaciens,
    [Show full text]
  • Deliciously Frozen Probiotics—Ice Cream and Beyond
    [Frozen/Refrigerated Foods] Vol. 20 No. 8 August 2010 ww Deliciously Frozen Probiotics—Ice Cream and Beyond By Cindy Hazen, Contributing Editor Given a choice between cultured buttermilk or a bowl of ice cream, most Americans would choose the latter. Buttermilk may be a healthier option, because it feeds us friendly bacteria that fortify our digestive system, but ice cream is infinitely more satisfying—even if we perceive it to offer us mostly flavor and calories. Adding probiotic bacteria to ice cream and frozen desserts Sweet Sales removes potential guilt and gives us reason to enjoy our The U.S. ice cream and frozen-dessert favorite scoop. But for the manufacturer, adding these market reached $24.6 billion in 2009, microscopic organisms requires a little know-how. notes a Jan. 2010 report published by Packaged Facts, “Ice Cream and Probiotics: It’s alive Frozen Desserts in the U.S.: Markets and Opportunities in Retail and Foodservice, 6th edition." Sales are National Yogurt Association, McLean, VA, notes that projected to reach $26.5 billion by probiotics are living microorganisms, which upon ingestion 2014. Frozen yogurt represents an 8% in sufficient number, exert health benefits beyond basic share of U.S. frozen-dessert sales. Ice nutrition. “Probiotics need to be viable in order to have any cream, on the other hand, comprises nutritional value, and thus must be incorporated post- 59% of sales. Frozen novelties make up 30% of sales. Further, the report pasteurization," says Peggy Pellichero, senior food notes, “the trend has taken a turn in technologist—dairy team leader, David Michael & Co., that it now focuses primarily on Philadelphia.
    [Show full text]
  • Characterization of Commercial Probiotics: Antibiotic Resistance
    University of Nebraska - Lincoln DigitalCommons@University of Nebraska - Lincoln Dissertations, Theses, & Student Research in Food Food Science and Technology Department Science and Technology 8-2014 Characterization of Commercial Probiotics: Antibiotic Resistance, Acid and Bile Resistance, and Prebiotic Utilization Carmen Lucia Cano Roca University of Nebraska-Lincoln, [email protected] Follow this and additional works at: http://digitalcommons.unl.edu/foodscidiss Part of the Food Microbiology Commons Cano Roca, Carmen Lucia, "Characterization of Commercial Probiotics: Antibiotic Resistance, Acid and Bile Resistance, and Prebiotic Utilization" (2014). Dissertations, Theses, & Student Research in Food Science and Technology. 46. http://digitalcommons.unl.edu/foodscidiss/46 This Article is brought to you for free and open access by the Food Science and Technology Department at DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in Dissertations, Theses, & Student Research in Food Science and Technology by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln. i Characterization of Commercial Probiotics: Antibiotic Resistance, Acid and Bile Resistance, and Prebiotic Utilization by Carmen Lucia Cano Roca A THESIS Presented to the Faculty of The Graduate College at the University of Nebraska In Partial Fulfillment of Requirements For the Degree of Master of Science Major: Food Science and Technology Under the Supervision of Professor Jayne E. Stratton Lincoln, Nebraska August, 2014 ii Characterization of Commercial Probiotics: Antibiotic Resistance, Acid and Bile Resistance, and Prebiotic Utilization Carmen Lucia Cano Roca, M.S. University of Nebraska, 2014 Adviser: Jayne Stratton Probiotics, live microorganisms that beneficially affect the health of their host, must undergo extensive research to ensure they are safe for consumption and possess certain functional properties.
    [Show full text]
  • Engineered Cells for Production of Indole-Derivatives
    Downloaded from orbit.dtu.dk on: Oct 05, 2021 Engineered cells for production of indole-derivatives Kell, Douglas; Yang, Lei; Malla, Sailesh Publication date: 2020 Document Version Publisher's PDF, also known as Version of record Link back to DTU Orbit Citation (APA): Kell, D., Yang, L., & Malla, S. (2020). Engineered cells for production of indole-derivatives. (Patent No. WO2020187739). General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. Users may download and print one copy of any publication from the public portal for the purpose of private study or research. You may not further distribute the material or use it for any profit-making activity or commercial gain You may freely distribute the URL identifying the publication in the public portal If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. ) ( 2 (51) International Patent Classification: C07K 14/715 (2006.01) (21) International Application Number: PCT/EP2020/056828 (22) International Filing Date: 13 March 2020 (13.03.2020) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 19163 184.5 15 March 2019 (15.03.2019) EP (71) Applicant: DANMARKS TEKNISKE UNIVERSITET [DK/DK]; Anker Engelunds Vej 101 A, 2800 Kgs. Lyngby (DK). (72) Inventors: KELL, Douglas, Bruce; Chirk Manor, Trevor Rd, Chirk, Wrexham LL14 5HD (GB).
    [Show full text]